- Home
- UBER vs IRWD Comparison
UBER vs IRWD Comparison
Compare UBER & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UBER
- IRWD
- Stock Information
- Founded
- UBER 2009
- IRWD 1998
- Country
- UBER United States
- IRWD United States
- Employees
- UBER N/A
- IRWD N/A
- Industry
- UBER Business Services
- IRWD Biotechnology: Pharmaceutical Preparations
- Sector
- UBER Consumer Discretionary
- IRWD Health Care
- Exchange
- UBER Nasdaq
- IRWD Nasdaq
- Market Cap
- UBER N/A
- IRWD 150.9M
- IPO Year
- UBER 2019
- IRWD 2010
- Fundamental
- Price
- UBER $82.71
- IRWD $0.71
- Analyst Decision
- UBER Strong Buy
- IRWD Buy
- Analyst Count
- UBER 33
- IRWD 5
- Target Price
- UBER $93.70
- IRWD $4.94
- AVG Volume (30 Days)
- UBER 20.8M
- IRWD 4.2M
- Earning Date
- UBER 05-07-2025
- IRWD 05-07-2025
- Dividend Yield
- UBER N/A
- IRWD N/A
- EPS Growth
- UBER 808.82
- IRWD N/A
- EPS
- UBER 5.66
- IRWD N/A
- Revenue
- UBER $45,380,000,000.00
- IRWD $317,676,000.00
- Revenue This Year
- UBER $16.62
- IRWD N/A
- Revenue Next Year
- UBER $14.52
- IRWD N/A
- P/E Ratio
- UBER $14.54
- IRWD N/A
- Revenue Growth
- UBER 17.60
- IRWD N/A
- 52 Week Low
- UBER $54.84
- IRWD $0.59
- 52 Week High
- UBER $87.00
- IRWD $8.23
- Technical
- Relative Strength Index (RSI)
- UBER 62.87
- IRWD 29.40
- Support Level
- UBER $80.12
- IRWD $0.88
- Resistance Level
- UBER $86.57
- IRWD $0.98
- Average True Range (ATR)
- UBER 2.95
- IRWD 0.10
- MACD
- UBER 0.53
- IRWD 0.02
- Stochastic Oscillator
- UBER 77.36
- IRWD 11.74
About IRWD Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.